The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.

Clear cell renal cell carcinoma (ccRCC), the most common type of kidney malignancy, is an incurable disease characterized by multiple metabolic abnormalities, especially lipid accumulation and desaturation. Though great progresses have been made in understanding the mechanisms of ccRCC, metabolic abnormalities remain largely unclear. Here, we found lncRNA LINC01138 is highly expressed in ccRCC and is associated with poor patient survival. LINC01138 regulates ccRCC growth through sterol regulatory element-binding protein 1 (SREBP1)-mediated lipid desaturation. Mechanistically, we demonstrated that LINC01138 interacts with PRMT5 to increase arginine methylation and protein stability of SREBP1, promoting lipid desaturation and cell proliferation in ccRCC. Our study identified LINC01138 as a novel regulator of metabolic abnormalities in ccRCC, providing a potential therapeutic target for metabolic therapy.